News
12-16-2008, 06:08 AM
Expression of the microtubule-binding protein Tau is not a reliable means of selecting breast cancer patients for adjuvant paclitaxel chemotherapy, according to research led by The University of Texas M. D. Anderson Cancer Center. Presented Dec. 13, at the CRTC-AACR San Antonio Breast Cancer Symposium, the researchers found that Tau expression does predict survival, yet in an unexpected way. In earlier neoadjuvant studies, investigators from M. D.
More... (http://www.medicalnewstoday.com/articles/133056.php)
More... (http://www.medicalnewstoday.com/articles/133056.php)